BiotechTube

RN564

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteopenia

Conditions

Osteopenia, Osteoporosis, Bone Disease

Trial Timeline

Apr 1, 2011 → May 24, 2012

NCT ID
NCT01293487

About RN564

RN564 is a phase 1 stage product being developed by Pfizer for Osteopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT01293487. Target conditions include Osteopenia, Osteoporosis, Bone Disease.

What happened to similar drugs?

5 of 10 similar drugs in Osteopenia were approved

Approved (5) Terminated (0) Active (5)
✅Teriparatide + Zoledronic AcidEli LillyApproved
✅alendronate sodiumMerckApproved
✅zoledronic acid vs pamidronateNovartisApproved
✅Placebo + ibandronate [Bonviva/Boniva]RocheApproved
✅tibolone + raloxifenOrganonApproved
🔄zoledronic acidNovartisPhase 3
🔄Zoledronic Acid + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01293487Phase 1Completed

Competing Products

18 competing products in Osteopenia

See all competitors
ProductCompanyStageHype Score
Teriparatide + Zoledronic AcidEli LillyApproved
43
alendronate sodiumMerckApproved
43
zoledronic acidNovartisPhase 3
40
zoledronic acid vs pamidronateNovartisApproved
43
Zoledronic Acid + PlaceboNovartisPhase 3
40
BPS804 20mg/Kg + Placebo to 20mg/Kg BPS804NovartisPhase 2
35
Placebo + ibandronate [Bonviva/Boniva]RocheApproved
43
ibandronate [Bonviva/Boniva] + PlaceboRochePhase 3
40
Romosozumab + PlaceboAmgenPhase 1
29
Placebo + AMG 167AmgenPhase 1
29
AMG 167 + PlaceboAmgenPhase 1
29
Romosozumab + PlaceboAmgenPhase 1
29
DenosumabAmgenPhase 3
40
Romosozumab + PlaceboAmgenPhase 1
29
Dasatinib 100 Mg Oral TabletNovo NordiskPhase 2
39
risedronate + alendronateSanofiPhase 1
29
Menostar (Estradiol, BAY86-5435) + RaloxifeneBayerPhase 3
37
tibolone + raloxifenOrganonApproved
37